explore -WSS

explore

author：explore 2025-10-01 23:04:04 - browse：883

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Medicare to cover more brain scans related to Alzheimer’s drugs

entertainment

WSS

STAT Readout Newsletter: Today in biotech, life science news

Covid vaccine financial winners and losers, from Pfizer to Novavax

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Food as medicine: Medically tailored meals may get standardized

Better Therapeutics data on benefit with GLP

Cancer cells are shown to suck energy source from immune cells

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

Abortion pill Supreme Court ruling could impact entire drug industry

Medical leaders decry Supreme Court decision on affirmative action

Akero's treatment for NASH falls short in cirrhosis study

How one medical school became remarkably diverse

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Merck drug for rare lung condition set for approval in U.S.

BioMarin wins approval for gene therapy to treat hemophilia A

How should state employee insurance handle Wegovy?

knowledge

Takeaways from AdvaMed, the largest medical devices conference

States should stop sabotaging methadone treatment reform

There’s no way to know how good AI health technologies are

FDA's naming rule on biosimilars has undermined competition

Primary care physicians play key roles in Alzheimer's management

Covid vaccine financial winners and losers, from Pfizer to Novavax

hotspot

focus

entertainment

hotspot